BTCRC-BRE15-016

 

  • Study Title: A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016 (NCT02668666)
  • Status: Open to Accrual
  • Study Details: See BTCRC-BRE15-016 study page

BTCRC-ESO14-012

 

  • Study Title: A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012 (NCT02639065)
  • Status: Open to Accrual

BTCRC-GI13-002

 

  • Study Title: An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002 (NCT02575339)
  • Status: Open to Accrual
  • Study Details: See BTCRC-GI13-002 study page

BTCRC-GU15-023

 

  • Study Title: Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium GU15-023 (NCT02891161)
  • Status: Open to Accrual
  • Study Details: See BTCRC-GU15-023 study page

BTCRC-LUN15-017

 

  • Study Title: A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy (NCT03003468)
  • Status: Open to Accrual
  • Study Details: See BTCRC-LUN15-017 study page

BTCRC-GU14-003

 

  • Study Title: Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003 (NCT02348008)
  • Status: Closed to Accrual
  • Study Details: See BTCRC-GU14-003 study page